Portaccio, Emilio http://orcid.org/0000-0002-9662-1762
Betti, Matteo
De Meo, Ermelinda
Addazio, Ilaria
Pastò, Luisa
Razzolini, Lorenzo
Totaro, Rocco
Spitaleri, Daniele
Lugaresi, Alessandra
Cocco, Eleonora
Onofrj, Marco
Di Palma, Franco
Patti, Francesco
Maimone, Davide
Valentino, Paola
Torri Clerici, Valentina
Protti, Alessandra
Ferraro, Diana
Lus, Giacomo
Maniscalco, Giorgia Teresa
Brescia Morra, Vincenzo
Salemi, Giuseppe
Granella, Franco
Pesci, Ilaria
Bergamaschi, Roberto
Aguglia, Umberto
Vianello, Marika
Simone, Marta
Lepore, Vito
Iaffaldano, Pietro
Comi, Giancarlo
Filippi, Massimo
Trojano, Maria
Amato, Maria Pia
,
Funding for this research was provided by:
Università degli Studi di Firenze
Article History
Received: 25 March 2024
Revised: 12 May 2024
Accepted: 14 May 2024
First Online: 28 May 2024
Change Date: 4 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-024-12627-3
Declarations
:
: E. Portaccio received compensation for travel grants, participation in advisory board and/or speaking activities from Biogen, Merck Serono, Sanofi, Teva, Roche, BMS Cellgene, Janssen and Novartis; serves on the editorial board of Frontiers in Neurology and Brain Sciences. M. Betti reports no disclosures. E. De Meo reports no disclosures. I. Addazio reports no disclosures. L. Pastò received research support from Novartis, Biogen and speaker honoraria from Teva. L. Razzolini received research support from Novartis. R. Totaro received funding for travel or speaker honoraria from Alfa Wasserman, Bayer, Biogen, CLS Bering, Merck Serono, Novartis, Sanofi Aventis, Roche, and Teva. D. Spitaleri received honoraria as a consultant on scientific advisory boards by Bayer Schering, Novartis and Sanofi Aventis and compensation for travel from Novartis, Biogen, Sanofi Aventis, Teva and Merck. A. Lugaresi served as a Biogen, Merck, Mylan, Novartis, Roche, Sanofi/Genzyme and Teva Advisory Board Member. She received congress and travel/accommodation expense compensations or speaker honoraria from Biogen, Merck, Mylan, Novartis, Sanofi/Genzyme, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institutions received research grants from Novartis. E. Cocco received research grants and honoraria as a speaker and member of advisory boards by: Almirall, Bayer, Biogen Idec, Merck Serono, Novartis, Sanofi–Genzyme, Teva, Roche. M. Onofrj reports no disclosures. F. Di Palma reports no disclosures. F. Patti received honoraria for speaking activities by Almirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi–Genzyme, and Teva; he also served as advisory board member the following companies: Alexion, Almirall, BMS Cellgene, Janssen, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi–Genzyme, and Teva; he was also funded by Biogen, Merck, Novartis, Reload Association, Italian Health Minister, Italian University Minister University of Catania and FISM for epidemiological studies; he received grants for congress participation from Almirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi–Genzyme, and Teva. D. Maimone received compensations for congress and travel expenses and participation in advisory boards by Bayer, Biogen, Bristo Myers Squibb, Merck, Novartis, Roche, Sanofi. P. Valentino received grants to attend scientific congresses or speaker honoraria from Biogen, Merck Serono, Novartis, and Roche. V. Torri Clerici received honoraria for speaking or writing from Novartis, Sanofi–Genzyme, Almirall, Bristol Meyer Squibb and Horizon; she acted as an Advisory Board member for Biogen, Lundbeck, Novartis, Sanofi–Genzyme, Bristol Meyer Squibb, Roche, Almirall and Merck Serono. She is involved as principal investigator in clinical trials for Sanofi–Genzyme, FISM, Bristol Meyer Squibb, Roche and Merck Serono; she has received support for research projects from Almirall. A. Protti reports no disclosures. D. Ferraro has received travel grants and/or fees for speaking and/or advisory boards from Alexion, Biogen, Bristol-Myers Squibb, Celgene, Merck, Novartis, Roche, Sanofi. G. Lus reports no disclosures. G.T. Maniscalco received personal compensation from Serono, Biogen, Novartis, Roche and Teva for public speaking and advisory boards. V. Brescia Morra received grants to attend scientific congresses or speaker honoraria from Biogen, Merck Serono, Novartis, Roche, Sanofi/Genzyme, and Teva. G. Salemi received grants to attend scientific congresses or speaker honoraria from Biogen, Merck Serono, Novartis, Roche, Sanofi/Genzyme, Teva. Alexion, BMS Cellgene, and Horizon. F. Granella received grants to attend scientific congresses or speaker honoraria from Biogen, Merck Serono, Novartis, Roche, Sanofi/Genzyme, and Teva. I. Pesci reports no disclosures. R. Bergamaschi has served on scientific advisory boards for Biogen, Merck Serono, Novartis, Sanofi–Genzyme; received research support from Almirall, Bayer, Biogen, Merck Serono, Novartis, Sanofi–Genzyme; received support for travel and congress from Biogen, Roche, Merck Serono, Sanofi–Genzyme, Teva; received honoraria for speaking engagement from Biogen, Merck Serono, Novartis, Sanofi–Genzyme. U. Aguglia received grants to attend scientific congresses or speaker honoraria from Biogen, Merck Serono, Novartis, Roche, Sanofi/Genzyme, and Teva. M. Vianello received compensation for travel grants or speaking activities from Biogen, Merck Serono, Roche, BMS Cellgene, Janssen and Novartis. M. Simone reports no disclosures. V. Lepore reports no disclosures. P. Iaffaldano received grants to attend scientific congresses or speaker honoraria from Biogen, Merck Serono, Novartis, Roche, Sanofi/Genzyme, and Teva. G. Comi received consulting fees from Actelion, Bayer Schering, Merck Serono, Novartis, Sanofi, and Teva, and lecture fees from Bayer Schering, Biogen Dompé, Merck Serono, Novartis, Sanofi, Serono, Symposia International Foundation, and Teva. M. Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi–Genzyme, Takeda, and Teva Pharmaceutical Industries; and still receives research support from Biogen Idec, Merck Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). M. Trojano received travel and/or Speaker honoraria from Sanofi Aventis, Genzyme, Biogen Idec, Teva, Merck, Serono and Novartis reported receiving speaker honoraria and research grants to her institution from and serving on advisory boards of Biogen, Merck Serono, and Novartis. M.P. Amato served on scientific advisory boards for and has received speaker honoraria and research support from Biogen Idec, Merck Serono, Bayer Schering Pharma, and Sanofi Aventis, and serves on the editorial board of Multiple Sclerosis Journal and BMC Neurology.
: The Italian Multiple Sclerosis Register was approved by the Policlinico of Bari Ethics Committee and by the local ethics committees in all participating centers. Written informed consent was obtained from all enrolled patients in accordance with the Declaration of Helsinki.